Abstracts tagged "glucocorticoids"

Abstract Number: 2597 • 2016 ACR/ARHP Annual Meeting
Time to Initiation of Biologic Agents Is Associated with Glucocorticoid Use: Results from the Corrona Registry
Dimitrios A. Pappas^1,2, Jenny Griffith³, Heather J. Litman², Casey A. Schlacher³, Bob A. Salim⁴, Chitra Karki² and Joel M. Kremer⁵, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³AbbVie Inc., North Chicago, IL, ⁴Axio Research LLC, Seattle, WA, ⁵Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Despite new effective therapies for Rheumatoid Arthritis (RA), glucocorticoids (GC) are widely prescribed. It is possible that dose and duration of GC therapy may…
Abstract Number: 2606 • 2016 ACR/ARHP Annual Meeting
Effect of Glucocorticoids on Clinical and Radiographic Efficacy Outcomes in Methotrexate-Naive Patients with RA Receiving Tofacitinib or Methotrexate Monotherapy: Analysis of Data from a Phase 3 Trial
Christina Charles-Schoeman¹, Désirée van der Heijde², Gerd Burmester³, Peter Nash⁴, Cristiano A.F Zerbini⁵, Carol A Connell⁶, Haiyun Fan⁷, Kenneth Kwok⁸, Eustratios Bananis⁷ and Roy Fleischmann⁹, ¹University of California, Los Angeles, Los Angeles, CA, ²Leiden University Medical Center, Leiden, Netherlands, ³Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁵Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, New York, NY, ⁹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients (pts) with RA often receive concomitant treatment with glucocorticoids (GCs) to…
Abstract Number: 2653 • 2015 ACR/ARHP Annual Meeting
Diagnostic Value of the Prednisolone Test in Patients with Possible Rheumatoid Arthritis
Uta Kiltz¹, Christine von Zabern¹, Xenofon Baraliakos¹, Frank Heldmann¹, Bernhard Mintrop¹, Michael Sarholz¹, Martin van Werde¹, Claudia Klink², Dietmar Krause², Friedrich Dybowski³, Ludwig Kalthoff³, Liane Hein³ and Juergen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Private rheumatology office, Gladbeck, Germany, ³Private rheumatology office, Herne, Germany
Background/Purpose: In patients with tender and swollen finger joints, the differential diagnosis between rheumatoid arthritis (RA) and osteoarthritis (OA) of the hands can be initially…
Abstract Number: 51 • 2015 ACR/ARHP Annual Meeting
Oral Glucocorticoid Use Is Associated with Osteonecrosis in Adults with Chronic Inflammatory Diseases but Not in Children: A Population-Based Cohort Study
Daniel B. Horton^1,2,3, Kevin Haynes^1,4, Michelle R. Denburg^1,5, Mihir Thacker⁶, Carlos D. Rose², Mary E. Putt¹, Mary B. Leonard⁷ and Brian L. Strom^1,3, ¹Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Pediatrics, Nemours A.I. duPont Hospital for Children, Division of Pediatric Rheumatology, Thomas Jefferson University, Wilmington, DE, ³Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ⁴Clinical Epidemiology, HealthCore, Wilmington, DE, ⁵Pediatrics, Children’s Hospital of Philadelphia, Division of Nephrology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Orthopedics, Nemours A.I. duPont Hospital for Children, Thomas Jefferson University, Wilmington, DE, ⁷Pediatrics, Division of Nephrology, Stanford School of Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Glucocorticoids have long been linked to the development of osteonecrosis, mostly in heavily exposed patients from specialty clinics. We tested the hypothesis that oral…
Abstract Number: 283 • 2015 ACR/ARHP Annual Meeting
Altered Serum Fatty Acid Profiles in Patients with Polymyositis or Dermatomyositis Compared to Healthy Individuals and in Relation to Immunosuppressive Treatment
Joan Raouf¹, Helena Idborg¹, Petter Olsson², Per Johan Jakobsson¹, Ingrid E. Lundberg¹ and Marina Korotkova¹, ¹Medicine, Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet S-171 76, Stockholm, Sweden, Stockholm, Sweden, ²Analytical Chemistry, Department of Analytical Chemistry, Stockholm University, Sweden, Stockholm, Sweden
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are chronic autoimmune diseases, characterized by muscle fatigue. Despite conventional immunosuppressive treatment including high doses of glucocorticoids, only a…
Abstract Number: 349 • 2015 ACR/ARHP Annual Meeting
Comparison Between the American Recommendations and the Japanese Guidelines for Glucocorticoid-Induced Osteoporosis in Japanese Patients with Rheumatoid Arthritis
Takefumi Furuya, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: In 2014, the Japanese Society for Bone and Mineral Research (JSBMR) updated their guidelines for the management and treatment of glucocorticoid-induced osteoporosis (GIO) and…
Abstract Number: 353 • 2015 ACR/ARHP Annual Meeting
A Longitudinal Cohort Study of Weekly Teriparatide, Denosmab, and Bisphosphonates for Prevention of Vertebral Fractures in Glucocorticoid-Induced Osteoporosis
Hisaji Oshima¹, Mari Ushikubo¹, Kumiko Akiya¹, Ikuko Tanaka², Shigenori Tamaki² and Keisuke Izumi³, ¹Department of Connective Tissue Diseases, National Tokyo Medical Center, Tokyo, Japan, ²NAGOYA Rheumatology Clinic, Nagoya, Japan, ³National Tokyo Medical Center, Tokyo, Japan
Background/Purpose: Although weekly teriparatide (56.5ug, wTPTD) and denosmab (DMAB) have been developed as potent anti-osteoporotic agents, effects of these agents on prevention of osteoporotic fractures…
Abstract Number: 356 • 2015 ACR/ARHP Annual Meeting
Assessment of the Effect of 12 Months Administration of Denosumab in Patients with Rheumatic Diseases
Kosuke Ebina¹, Makoto Hirao², Jun Hashimoto³, Keisuke Hagihara⁴, Hideki Yoshikawa⁵ and Takaaki Noguchi⁶, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁴Kampo Medicine, Osaka University, Graduate School of Medicine, Suita, Japan, ⁵Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan, ⁶Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan
Background/Purpose: In patients with rheumatic diseases (RD), pro-inflammatory cytokines induce receptor activator of nuclear factor kappa-B ligand (RANKL), which plays a crucial role in inducing…
Abstract Number: 380 • 2015 ACR/ARHP Annual Meeting
Osteoporosis Screening and Treatment of Rheumatoid Arthritis Patients at a Teaching Institution
Sheena Ogando¹, Calie Santana², Irene Blanco³ and Barbara Mendez¹, ¹Rheumatology, Montefiore Medical Center, Bronx, NY, ²Medicine, Montefiore Medical Center, Bronx, NY, ³Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Glucocorticoids are effective at treating rheumatologic diseases but are known to increase fracture risk. In 2010, the ACR developed recommendations for the prevention…
Abstract Number: 538 • 2015 ACR/ARHP Annual Meeting
Multidrug Resistant Lymphocytes of Patients with Rheumatoid Arthritis Are Predictive for DMARD and Glucocorticoid Treatment Response
Jan Piet van Hamburg¹, Sandra M.J. Paulissen², Nadine Davelaar¹, Mieke Hazes³ and Erik Lubberts¹, ¹Rheumatology and Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, ²Room Nb-84, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, ³Rheumatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
Background/Purpose: A large fraction of patients with RA does not respond to treatment with glucocorticoids (GCs) and disease-modifying anti-rheumatic drugs (DMARDs), or becomes resistant in…
Abstract Number: 559 • 2015 ACR/ARHP Annual Meeting
Herpes Zoster and Tofacitinib: The Risk of Concomitant Nonbiologic Therapy
Kevin L. Winthrop¹, Jeffrey R. Curtis², Stephen Lindsey³, Hernan Valdez⁴, Haiyun Fan⁵, Lisy Wang⁶, Alan M. Mendelsohn⁵ and Eustratios Bananis⁵, ¹Oregon Health & Science University, Portland, OR, ²The University of Alabama at Birmingham, Birmingham, AL, ³Ochsner Medical Center, Baton Rouge, LA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Patients with RA are at increased risk for herpes zoster (HZ). Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Treatment…
Abstract Number: 587 • 2015 ACR/ARHP Annual Meeting
Defining the Conditions Under Which Long-Term Glucocorticoid Treatment Has a Good Benefit-Risk Ratio
Cindy Strehl¹, Johannes W J Bijlsma², Maarten de Wit³, Maurizio Cutolo⁴, Raphaele Seror⁵, Kevin L. Winthrop⁶, Frank Buttgereit¹ and EULAR Task Force on Glucocorticoids, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Medical Humanities, VU Medical Centre, Amsterdam, Netherlands, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ⁵Department of Rheumatology, Assistance Publique–Hopitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre, France, ⁶Division of Infectious Diseases, Oregon Health and Science University, Portland, OR
Background/Purpose: Glucocorticoids (GC) are used to treat a wide range of inflammatory diseases including rheumatic and musculoskeletal diseases. EULAR recommendations on GC therapy are up…
Abstract Number: 884 • 2015 ACR/ARHP Annual Meeting
Patient Perceptions of Treatment with Glucocorticoids in ANCA-Associated Vasculitis
Joanna Robson¹, Susan Ashdown², Jill Dawson³, Ebony Easley⁴, Don Gebhart⁵, Katherine Kellom⁶, Georgia Lanier⁷, Nataliya Milman⁸, Jacqueline Peck⁹, Judy A. Shea¹⁰, Peter F. Cronholm⁴ and Peter A. Merkel¹¹, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ²NONE, Branbury, United Kingdom, ³Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, ⁴Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ⁵NONE, Columbus, OH, ⁶PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, ⁷NONE, Framingham, MA, ⁸Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ⁹NONE, Oxford, United Kingdom, ¹⁰Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, United Kingdom, ¹¹Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) comprise a group of multisystem diseases of the small blood vessels…
Abstract Number: 1220 • 2015 ACR/ARHP Annual Meeting
Oral Glucocorticoid Prescribing Patterns in UK Primary Care for Patients with Rheumatoid Arthritis
Rachel J Black^1,2, Rebecca M Joseph^3,4, Mohammad Movahedi², Mark Lunt² and William G Dixon^2,5, ¹Department of Medicine, The University of Adelaide, Adelaide, Australia, ²Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Manchester Academic Health Science Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ⁵Manchester Academic Health Sciences Centre, Health e-Research Centre, Farr Institute for Health Informatics Research, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Oral glucocorticoids (GCs) are commonly used in the treatment of rheumatoid arthritis (RA). Although GPs don’t typically alter DMARD prescriptions, changes to GC therapy…
Abstract Number: 1634 • 2015 ACR/ARHP Annual Meeting
The Effects of Glucocorticoids on the Efficacy of Tofacitinib As Monotherapy and in Combination Therapy with Nonbiologic Dmards: An Analysis of Data from Six Phase 3 Studies
Roy Fleischmann¹, Christina Charles-Schoeman², Gerd Burmester³, Cristiano Zerbini⁴, Peter Nash⁵, Kenneth Kwok⁶, Koshika Soma⁷, Alan Mendelsohn⁸ and Eustratios Bananis⁸, ¹Metroplex Clinical Research Center, Dallas, TX, ²University of California, Los Angeles, CA, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁵Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients with RA often receive concomitant treatment with glucocorticoids (GCs) to control…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].